New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
91% of infants treated with Evrysdi in the FIREFISH study were still alive at three years
Infants treated with Evrysdi maintained or continued to improve in measures of motor function, including their ability to sit without support for 5 and 30 seconds
Evrysdi has proven efficacy in infants and adults, with more than 5,000 patients treated to date
